Physician profile
Minxin Fu
NPI 1205952397
$2,067.52
in general payments reported to CMS, 2019-2025
23 companies · $19.89 in 2025
The $19.89 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $359 · 2021: $441 · 2022: $353 · 2023: $127 · 2025: $19.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $350.68 | 2019-2025 | Penmenvy |
| Ironshore Pharmaceuticals INC. | $345.38 | 2019-2020 | |
| Tris Pharma INC | $281.60 | 2019-2021 | |
| Pfizer INC. | $224.36 | 2019-2020 | |
| Genzyme Corporation | $126.62 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.16 | 2020-2021 | |
| Novo Nordisk INC | $98.94 | 2022 | |
| Adlon Therapeutics L.P. | $96.24 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.61 | 2022 | |
| Supernus Pharmaceuticals, INC. | $77.43 | 2022 | |
| Amarin Pharma, INC. | $48.30 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $46.49 | 2021 | |
| Neos Therapeutics, LP | $29.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.76 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.09 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.19 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.68 | 2021 | |
| Sobi, INC | $15.57 | 2019 | |
| Corium, LLC | $14.01 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.75 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.43 | 2021 | |
| Eisai INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minxin Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.